Prognostic Factors for Advanced Breast Cancer

Yanxi Liu

doi:10.54254/2753-8818/2025.21569

Research Article

Open access

Published on 20 March 2025

Download pdf

Liu,Y. (2025). Prognostic Factors for Advanced Breast Cancer. Theoretical and Natural Science,96,47-53.

Export citation

Prognostic Factors for Advanced Breast Cancer

Yanxi Liu *^,1,

¹ Second Clinical Medical School, LanZhou University, 222 Tianshui South Road, Chengguan District, Lanzhou, China

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/2025.21569

Abstract

Breast cancer is one of the most frequent malignancies affecting women’s health and is the second leading tumor in terms of prevalence globally. However, advanced breast cancer remains incurable, and the prognosis is unfavorable. Identifying prognostic factors in advanced breast cancer is crucial for clinical practice. In this paper, we aim to summarize significant risk factors affecting the prognosis of patients suffering from advanced breast carcinoma, including age, sites of metastasis, molecular typing, and local treatments. Additionally, this paper explores the methods and functions of prediction models for advanced breast cancer, aiming at offering new insights for clinicians and researchers. In the future, with a large body of research, we hope clinical researchers will develop prediction models for advanced breast cancer that are widely applicable in clinical practice. These models could enable patients to have a clearer and more in - depth understanding of their conditions and assist physicians in implementing individualized treatments and precision medicine, ultimately prolonging patient survival.

Keywords

Advanced breast cancer, Prognostic factors, Survival

View pdf

References

[1]. Wang, X., & Xue, Y. (2024). Treatment exploration of elderly patients with advanced breast cancer. Yiyao Daobao, 43(3), 360-365.

[2]. Zhang, Z., Sun, J., Zhang, L., et al. (2021). Risk factors and prognostic factors analysis for breast cancer with bone metastasis. Clinical Surgery Journal, 29(3), 243-247.

[3]. Bianchini, G., De Angelis, C., Licata, L., et al. (2022). Treatment landscape of triple-negative breast cancer—expanded options, evolving needs. Nature Reviews Clinical Oncology, 19(2), 91-113.

[4]. Sun, C., Zhao, J., Han, B., et al. (2024). Network meta-analysis of the safety of four CDK4/6 inhibitors for advanced breast cancer. Cancer Pharmacy, 14(4), 479-488.

[5]. Zheng, W., & Liu, Q. (2024). Year-end review of clinical research progress on breast cancer in 2023. Chinese Journal of General Surgery, 33(5), 669-682.

[6]. Yang, R. (2023). Clinical characteristics and prognosis of patients with breast cancer metastasis in different sites (Master’s thesis, Jilin University). https://doi.org/10.27162/d.cnki.gjlin.2023.005943.

[7]. Wang, X., & Xue, Y. (2024). Treatment exploration of elderly patients with advanced breast cancer. Yiyao Daobao, 43(3), 360-365.

[8]. Advances in Clinical Medicine. (2021). Clinical medicine advancements. Advances in Clinical Medicine, 11(12), 5613-5619. https://doi.org/10.12677/acm.2021.1112831.

[9]. Gao, L. (2024, October 30). Breast cancer has fully entered the “chronic disease era”. China Women’s Daily, (008).

[10]. Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. https://doi.org/10.1007/s10549-016-4066-7

[11]. Won, K. A., & Spruck, C. (2020). Triple-negative breast cancer therapy: Current and future perspectives (Review). International Journal of Oncology, 57(6), 1245-1261. https://doi.org/10.3892/ijo.2020.5135 Epub 2020 Oct 16. PMID: 33174058; PMCID: PMC7646583.

[12]. Morrison, L., & Okines, A. (2023). Systemic therapy for metastatic triple-negative breast cancer: Current treatments and future directions. Cancers (Basel), 15(15), 3801. https://doi.org/10.3390/cancers15153801 PMID: 37568617; PMCID: PMC10417818.

[13]. Molecular mechanisms of breast cancer metastasis to the lungs: Clinical and experimental perspectives. International Journal of Molecular Sciences, 9(2272), 10. https://doi.org/3390/ijms31071959 PMID:6540248;PMCID:PMC<>｡

[14]. Zouki, D. N., Karatrasoglou, E. A., Pilichos, G., & Papadimitraki, E. (2024). Oligometastatic breast cancer: Seeking the cure by redefining stage IV disease? Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01275-4 Epub ahead of print. PMID: 39541082.

[15]. Ivanova, M., Porta, F. M., Giugliano, F., Frascarelli, C., Sajjadi, E., Venetis, K., Cursano, G., Mazzarol, G., Guerini-Rocco, E., Curigliano, G., Criscitiello, C., & Fusco, N. (2023). Breast cancer with brain metastasis: Molecular insights and clinical management. Genes (Basel), 14(6), 1160. https://doi.org/10.3390/genes14061160 PMID: 37372340; PMCID: PMC10298724.

[16]. Sun, H., Xu, J., Dai, S., Ma, Y., & Sun, T. (2023). Breast cancer brain metastasis: Current evidence and future directions. Cancer Medicine, 12(2), 1007-1024. https://doi.org/10.1002/cam4.5021 Epub 2022 Jul 13. PMID: 35822637; PMCID: PMC9883555.

[17]. Jiang, Z., Chen, J., Niu, X., et al. (2015). Clinical diagnosis and treatment expert consensus on bone metastasis and bone-related diseases in breast cancer (2014 edition). Chinese Medical Journal, 95(4), 241-247.

[18]. Blanchard, D. K., Shetty, P. B., Hilsenbeck, S. G., & Elledge, R. M. (2008). Association of surgery with improved survival in stage IV breast cancer patients. Annals of Surgery, 247(5), 732-738. https://doi.org/10.1097/SLA.0b013e3181656d32 PMID: 18438108.

[19]. Babiera, G. V., Rao, R., Feng, L., Meric-Bernstam, F., Kuerer, H. M., Singletary, S. E., Hunt, K. K., Ross, M. I., Gwyn, K. M., Feig, B. W., Ames, F. C., Hortobagyi, G. N. (2006). Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Annals of Surgical Oncology, 13(6), 776-782. https://doi.org/10.1245/ASO.2006.03.033 Epub 2006 Apr 17. PMID: 16614878.

[20]. Rosche, M., Regierer, A. C., Schwarzlose-Schwarck, S., Weigel, A., Bangemann, N., Schefe, J. H., Scholz, C. W., Possinger, K., & Eucker, J. (2011). Primary tumor excision in stage IV breast cancer at diagnosis without influence on survival: A retrospective analysis and review of the literature. Oncology, 34(11), 607-612. https://doi.org/10.1159/000334061 Epub 2011 Oct 28. PMID: 22104157.

[21]. Local therapy and survival in breast cancer with distant metastases. https://doi.org/10.1002/jso.22056

[22]. Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China. https://creativecommons.org/licenses/by-nc-nd/4.0/

[23]. Li, S., Zhao, J., Zhu, L., Su, F., & Chen, K. (2017). Development and validation of a nomogram predicting the overall survival of stage IV breast cancer patients. Cancer Medicine, 6(11), 2586-2594. https://doi.org/10.1002/cam4.1224 Epub 2017 Oct 4. PMID: 28980424; PMCID: PMC5673913.

[24]. Lee, C. K., Hudson, M., Stockler, M., Coates, A. S., Ackland, S., Gebski, V., et al. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129, 467–476.

[25]. Lee, E. S., Jung, S. Y., Kim, J. Y., Kim, J. J., Yoo, T. K., Kim, Y. G., et al. (2016). Identifying the potential long-term survivors among breast cancer patients with distant metastasis. Annals of Oncology, 27(6), 828–833.

[26]. Lobbezoo, D. J., van Kampen, R. J., Voogd, A. C., Dercksen, M. W., van den Berkmortel, F., Smilde, T. J., et al. (2015). Prognosis of metastatic breast cancer: Are there differences between patients with de novo and recurrent metastatic breast cancer? British Journal of Cancer, 112(9), 1445–1451.

Cite this article

Liu,Y. (2025). Prognostic Factors for Advanced Breast Cancer. Theoretical and Natural Science,96,47-53.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 5th International Conference on Biological Engineering and Medical Science

Conference website: https://2025.icbiomed.org/

ISBN：978-1-83558-985-4(Print) / 978-1-83558-986-1(Online)

Conference date: 24 October 2025

Editor：Alan Wang

Series: Theoretical and Natural Science

Volume number: Vol.96

ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).